Skip to main content
. 2018 Nov 21;56(7):5067–5074. doi: 10.1007/s12035-018-1426-9

Table 1.

Group characteristics

Discovery Validation
Control PD p value* Control PD APD p value*
Demographics
n 10 10 44 37 21
 Age at inclusion (years) 59 ± 7 61 ± 8 p = 0.4 58 ± 10 57 ± 10 64 ± 7 p = 0.02
 Sex (male/female) 6/4 7/3 p = 1.0 21/23 24/13 13/8 p = 0.26
 Disease duration (months) NA 37 ± 17 NA 36 ± 34 31 ± 23 p = 0.92
 DM (no/yes) NA 9/1 NA 31/6 14/7
CSF parameters
 Gal-1# 5E+06 ± 4E+06 6E+05 ± 2E+06 p = 0.02 6961 ± 3475 6046 ± 2631 7133 ± 3795 p = 0.46
 Total protein (mg/L) 468 ± 66 492 ± 54 p = 0.4 547 ± 644 530 ± 182 591 ± 273 p < 0.001
 Gal-1/total protein (ng/mg) NA NA 17 ± 9 11 ± 5 14 ± 9 p = 0.003
 α-Syn (μg/L) NA 24 ± 9 NA n = 37 n = 20 p = 0.60
29 ± 12 30 ± 12
 NFL (ng/L) NA 1415 ± 528 NA n = 37 n = 20 p < 0.0001
1122 ± 639 4511 ± 3633
 Total tau (ng/L) NA 273 ± 150 NA n = 37 n = 21 p = 0.55
202 ± 71 260 ± 111
 Phosphorylated tau (ng/L) n = 37 n = 21 p = 0.92
NA 58 ± 27 NA 48 ± 16 49 ± 15
Disease severity
 Baseline
 H&Y score NA n = 10 NA n = 36 n = 21 p < 0.0001
2 ± 0 2 ± 1 3 ± 1
 UPDRS score NA n = 10 NA n = 35 n = 21 p = 0.046
22 ± 6 26 ± 13 33 ± 13
 ICARS score NA n = 9 NA n = 33 n = 16 p < 0.001
2 ± 2 2 ± 3 10 ± 11
 MMSE score NA n = 10 NA n = 37 n = 20 p = 0.10
29 ± 1 28 ± 2 27 ± 3
Follow-up
  H&Y score NA n = 9 NA n = 35 n = 14 p < 0.0001
2 ± 1 2 ± 1 4 ± 1
  UPDRS score NA n = 7 NA n = 33 n = 11 p = 0.049
28 ± 10 29 ± 13 37 ± 9
  ICARS score NA n = 7 NA n = 30 n = 11 p < 0.001
2 ± 1 3 ± 3 12 ± 10
  MMSE score NA n = 8 NA n = 30 n = 11 p = 0.05
29 ± 1 28 ± 3 26 ± 3

Values are expressed as mean ± standard deviation

n number of samples, DM intake of dopaminergic medication at CSF collection, CSF cerebrospinal fluid, Gal-1 galectin-1, α-syn α-synuclein, PD Parkinson’s disease, APD atypical parkinsonism, NA not applicable, H&Y Hoehn and Yahr score, UPDRS Unified Parkinson’s Disease Rating Scale, ICARS International Cooperative Ataxia Rating Scale, MMSE mini-mental state examination score

#Units: in discovery cohorts, arbitrary intensity; in validation cohorts, ng/L

*Parameters were analyzed with Kruskal–Wallis test when data of the three groups was available. For comparisons between two groups Student’s t test or Mann–Whitney U test, except for sex, which was analyzed using chi-squared test; In italic p-value below 0.05